Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
NeoTX Therapeutics Ltd.
Maastricht University Medical Center
UNICANCER
Ludwig Institute for Cancer Research